Search

Your search keyword '"Doehner, Konstanze"' showing total 319 results

Search Constraints

Start Over You searched for: Author "Doehner, Konstanze" Remove constraint Author: "Doehner, Konstanze"
319 results on '"Doehner, Konstanze"'

Search Results

1. AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology

2. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

3. Netboost: Boosting-supported network analysis improves high-dimensional omics prediction in acute myeloid leukemia and Huntington's disease

4. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

5. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

6. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

7. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

9. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

10. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

11. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

12. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice

13. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

14. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

15. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

18. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

19. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

20. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

23. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

24. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

25. Disease evolution and outcomes in familial AML with germline CEBPA mutations

27. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

28. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

29. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications

30. Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

31. Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

32. Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

34. Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

35. Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

36. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

37. Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

38. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

39. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

40. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

41. How a Medical Association Can Make a Difference in a Crisis Situation

42. An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia

43. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

44. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia

47. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations

48. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

50. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

Catalog

Books, media, physical & digital resources